Phase 2 trial data indicate that the most common side effects are gastrointestinal including nausea, vomiting, diarrhoea, and constipation particularly during dose escalation, which is consistent with other GLP-1-containing therapies
Malik AA, Puissant J, Buckeridge KM, Goodall T, Jehmlich N, Chowdhury S, Gweon HS, Peyton JM, Mason KE, van Agtmaal M, Blaud A, Clark IM, Whitaker J, Pywell RF, Ostle N, Gleixner G, Griffiths RI
A doctor or nurse will provide full instructions on how to inject it correctly
Practical steps for day one: Keep a symptom diary from the outset Stay well hydrated throughout the day Avoid large, heavy, or high-fat meals immediately after your injection Have your healthcare team's and trial team's contact details readily available If you experience urgent or worsening symptoms, call NHS 111 for advice
By activating the GLP-1 and GIP receptors in the body, tirzepatide effectively helps to reduce appetite and increase the feeling of fullness after meals, which can lead to weight loss
For more specific dosage guidance for Wegovy and Mounjaro, check out our information pages: Mounjaro vs Wegovy: Effectiveness Several Mounjaro studies have been carried out, with the most important for weight loss being SURMOUNT-1